An Analysis of the Improvement and Quality of Life Trends for UK/ROI Patients Treated With Cosentyx (Secukinumab) in a Retrospective Analysis of the BADBIR Data Source
Latest Information Update: 13 May 2022
At a glance
- Drugs Secukinumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 13 May 2022 New trial record